EP 3802573 A1 20210414 - VACCINE COMPOSITION COMPRISING RECOMBINANT PROTEIN OF STAPHYLOCOCCUS AUREUS ATTENUATED ENTEROTOXIN AND CYTOTOXIN
Title (en)
VACCINE COMPOSITION COMPRISING RECOMBINANT PROTEIN OF STAPHYLOCOCCUS AUREUS ATTENUATED ENTEROTOXIN AND CYTOTOXIN
Title (de)
IMPFSTOFFZUSAMMENSETZUNG MIT REKOMBINANTEM PROTEIN VON ABGESCHWÄCHTEM ENTEROTOXIN UND CYTOTOXIN VON STAPHYLOCOCCUS AUREUS
Title (fr)
COMPOSITION DE VACCIN COMPRENANT UNE PROTÉINE RECOMBINÉE D'ENTÉROTOXINE ATTÉNUÉE ET DE CYTOTOXINE DE STAPHYLOCOCCUS AUREUS
Publication
Application
Priority
- KR 20180066226 A 20180608
- KR 2018015865 W 20181213
Abstract (en)
[origin: WO2019235705A1] The present invention relates to a vaccine composition comprising a Staphylococcus aureus attenuated enterotoxin protein and cytotoxin protein, and more particularly to a Staphylococcus aureus enterotoxin protein, a Staphylococcus aureus cytotoxin protein, a vaccine composition for prevention of bovine mastitis, comprising the Staphylococcus aureus enterotoxin protein and Staphylococcus aureus cytotoxin protein and a method for preventing bovine mastitis comprising administering the vaccine composition to a bovine. The Staphylococcus aureus enterotoxin protein, the Staphylococcus aureus cytotoxin protein according to the present invention, and the vaccine composition comprising the proteins as an antigen can be used so that even vaccines comprising several antigens rather than all kinds of antigens show the excellent effects of prevention and treatment of bovine mastitis against all kinds of Staphylococcus aureus enterotoxin and cytotoxin having high incidence in Korea, thereby being more economically used for industrial purposes. Further, the vaccine composition for prevention of bovine mastitis, comprising the Staphylococcus aureus enterotoxin protein and Staphylococcus aureus cytotoxin protein according to the present invention has an excellent safety and bovine mastitis prevention and treatment effect even in the high CFU Staphylococcus aureus challenge test so that the composition can be variously utilized in Staphylococcus aureus vaccine and prevention related fields in future.
IPC 8 full level
C07K 14/31 (2006.01); A61K 39/00 (2006.01); A61K 39/085 (2006.01)
CPC (source: EP KR US)
A61K 39/085 (2013.01 - EP KR US); C07K 14/31 (2013.01 - EP KR US); A61K 2039/552 (2013.01 - EP KR US); A61K 2039/55505 (2013.01 - EP KR US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2019235705 A1 20191212; EP 3802573 A1 20210414; EP 3802573 A4 20220427; KR 102061735 B1 20200102; KR 20190139583 A 20191218; US 11285199 B2 20220329; US 2021170010 A1 20210610
DOCDB simple family (application)
KR 2018015865 W 20181213; EP 18921463 A 20181213; KR 20180066226 A 20180608; US 201816972887 A 20181213